Press release
Antiepileptic Drugs Market to Reach US$ 26.2 Billion by 2032, Growing at a CAGR of 4.3%
Antiepileptic Drugs Market
Epilepsy is a condition that causes repeated seizures that are not brought on by localized or severe brain shocks. Epilepsy is linked to gradual impairments in cognitive functioning, neurological damage, and other cerebral impairments if it is left untreated. Antiepileptic medications (AEDs) are prescribed to patients who have epilepsy to reduce the frequency and/or severity of their seizures.
Experience The Cutting-Edge Of Innovation And Success With Our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-3341
After headaches, epilepsy is the second most prevalent neurological disorder. Since it has a significant financial impact on the health care system and imposes a significant morbidity burden on both individuals and society, it is a major concern for public health. It is characterized by repeated seizures with cerebral etiology.
Numerous medicines used to treat epilepsy frequently result in severe poisonings. AEDs do not have a perfect pharmacokinetic profile, which makes them suitable for both therapeutic and toxicity monitoring. Currently, tailoring the dosage to the patient's specific requirements and keeping an eye on adequate blood concentrations is very advantageous for patients utilizing different AEDs.
The growing ageing population, rising burden of neurological conditions, and rising disposable income, are thus the factors driving the demand for the global antiepileptic drugs market.
Key Takeaways from Market Study:
• Second generation of antiepileptic drugs are the leading segment as drug generation, and hold approximately 53.4% market share in 2021. In comparison to first-generation medications, second generation AEDs have a lower risk of teratogenesis and a more favorable side-effect profile.
• Oral route of administration segment is set to lead in terms of route of administration of antiepileptic drugs with a market share of around 62.2% in 2021, owing to its ease of administration in pediatric and geriatric patients.
• By distribution channel, retail pharmacies are leading in the global antiepileptic drugs market, and are expected to continue to do so with a projected CAGR of 4.6% during the forecasted years.
• North America is considered as the leading region with a value share of 43.6% in 2021, owing to the high prevalence of neurological diseases in the region.
Ask from Market Research Expert! https://www.futuremarketinsights.com/ask-question/rep-gb-3341
"Rising prevalence of neurological and mood disorders has called for innovations within the antiepileptic drugs market sphere," says an analyst of Future Market Insights.
Market Competition:
Key market leaders are concentrating on receiving regulatory agency approvals, which is anticipated to propel the expansion of the worldwide antiepileptic drugs market. Key players are coming up with new drug profiles to widen their portfolio presence.
For instance:
• Pfizer, Inc. reported in July 2019 that the US Food and Drug Administration has approved the first Lyrica (pregabalin) generics for use as an adjunctive therapy for the management of partial onset seizures in patients aged 17 and older.
• In August 2021, Eisai Co., Ltd. announced that the National Medical Products Administration in China had granted its internally discovered and developed anti-epileptic drug (AED) Fycompa® two additional approvals as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older."
For more Report Customization, connect with us at! https://www.futuremarketinsights.com/customization-available/rep-gb-3341
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the antiepileptic drugs market in its latest study, presenting a historical demand assessment of 2012 - 2021 and projections for 2022 - 2032. The global antiepileptic drugs market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The research study is based on the drug generation - (first generation, second generation, and third generation), by route of administration (oral, and intravenous), by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and drug stores), across seven key regions of the world.
Key Companies Profiled:
• Merck KGaA
• Eisai Co., Ltd.
• AstraZeneca
• Novartis AG
• Abbott
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• GlaxoSmithKline plc
• Sanofi
• Johnson & Johnson Service, Inc.
• Dr. Reddy's Laboratories Ltd.
Inquire Before Buying This Research Report! https://www.futuremarketinsights.com/checkout/3341
Key Market Segments Covered in Antiepileptic Drugs Industry Research:
By Drug Generation:
• First Generation
• Second Generation
• Third Generation
By Route of Administration:
• Oral
• Intravenous
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)
Explore FMI's related ongoing Coverage on Healthcare Market Insights Domain:
Angiography Devices Market:
https://www.futuremarketinsights.com/reports/angiography-devices-market
Acetaminophen API Market: https://www.futuremarketinsights.com/reports/acetaminophen-api-market
Multiple Unit Pellet Systems Market: https://www.futuremarketinsights.com/reports/multiple-unit-pellet-systems-market
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
Browse Full Report: https://www.futuremarketinsights.com/reports/antiepileptic-drugs-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antiepileptic Drugs Market to Reach US$ 26.2 Billion by 2032, Growing at a CAGR of 4.3% here
News-ID: 3219309 • Views: …
More Releases from Future Market Insights Inc
Dried Soup Market Growth and Global Demand Surge A Comprehensive Analysis to Rea …
The dried soup market is predicted to develop at an impressive 7.9% CAGR from 2023 to 2033, preceding the lower 1.4% CAGR witnessed between 2018 and 2022. This significant rise shows the rise in demand for the dried soup market, increasing the market value from US$ 2.1 billion in 2023 to US$ 4.5 billion by 2033.
The desire for convenient eating options and the fast-paced lifestyle have increased demand for ready-to-eat…
Ethylene Carbonate Market Projected to Reach US$ 559.6 Million by 2032: FMI Fore …
According to Future Market Insights (FMI), a new market analysis projects that the worldwide ethylene carbonate market will grow at a 6.2% CAGR between 2022 and 2032. Organic compound ethylene carbonate, also referred to as EC, is one of them. It is a transparent, crystalline solid that is soluble in water and is an odorless, colorless chemical at room temperature. Ethylene carbonate is used in a wide range of end-use…
Banana Flakes Market Satisfying Global Demand for Healthier Foods with 4.6% CAGR …
According to a recent report by Future Market Insights, a market research and competitive intelligence provider, sales of Banana Flakes are estimated to reach a value of US$ 810.2 million by 2032, surging at 4.6% CAGR through the decade. The growing demand for organic goods in both developed and developing countries has a big influence on the global banana flakes market. As people become even more increasingly health-conscious across the…
Chickpea Flour Market Growth Soars Predicted to Reach US$ 6.70 Billion by 2032 A …
According to market study by Future Market Insights (FMI), chickpea flour market would reach around US$ 6.70 billion at 4.8% CAGR in 2032.
Because it is nutrient-rich and has a mild flavour, chickpea flour is perfect for both savoury and sweet dishes. The producers of chickpea flour are spending money on the development of new products as well, in order to please their sizable customer base. Chickpea flour is highly sought after by…
More Releases for Drug
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…
